AU2006236649B2 - Methods and compositions for modulating and detecting WISP activity - Google Patents

Methods and compositions for modulating and detecting WISP activity Download PDF

Info

Publication number
AU2006236649B2
AU2006236649B2 AU2006236649A AU2006236649A AU2006236649B2 AU 2006236649 B2 AU2006236649 B2 AU 2006236649B2 AU 2006236649 A AU2006236649 A AU 2006236649A AU 2006236649 A AU2006236649 A AU 2006236649A AU 2006236649 B2 AU2006236649 B2 AU 2006236649B2
Authority
AU
Australia
Prior art keywords
wisp
polypeptide
domain
cells
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006236649A
Other languages
English (en)
Other versions
AU2006236649A2 (en
AU2006236649A1 (en
Inventor
Luc Desnoyers
Ellen Filvaroff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AU2006236649A1 publication Critical patent/AU2006236649A1/en
Publication of AU2006236649A2 publication Critical patent/AU2006236649A2/en
Application granted granted Critical
Publication of AU2006236649B2 publication Critical patent/AU2006236649B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2006236649A 2005-04-14 2006-04-13 Methods and compositions for modulating and detecting WISP activity Ceased AU2006236649B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/105,876 US7455834B2 (en) 2002-06-29 2005-04-14 Methods and compositions for modulating and detecting WISP activity
US11/105,876 2005-04-14
PCT/US2006/014008 WO2006113402A1 (en) 2005-04-14 2006-04-13 Methods and compositions for modulating and detecting wisp activity

Publications (3)

Publication Number Publication Date
AU2006236649A1 AU2006236649A1 (en) 2006-10-26
AU2006236649A2 AU2006236649A2 (en) 2008-07-24
AU2006236649B2 true AU2006236649B2 (en) 2012-03-29

Family

ID=36809580

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006236649A Ceased AU2006236649B2 (en) 2005-04-14 2006-04-13 Methods and compositions for modulating and detecting WISP activity

Country Status (16)

Country Link
US (2) US7455834B2 (cg-RX-API-DMAC7.html)
EP (1) EP1869086B1 (cg-RX-API-DMAC7.html)
JP (1) JP4979684B2 (cg-RX-API-DMAC7.html)
KR (1) KR101320261B1 (cg-RX-API-DMAC7.html)
CN (1) CN101198623B (cg-RX-API-DMAC7.html)
AU (1) AU2006236649B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0612184A8 (cg-RX-API-DMAC7.html)
CA (1) CA2604933C (cg-RX-API-DMAC7.html)
ES (1) ES2388993T3 (cg-RX-API-DMAC7.html)
IL (1) IL186095A (cg-RX-API-DMAC7.html)
MX (1) MX2007012798A (cg-RX-API-DMAC7.html)
NO (1) NO20075825L (cg-RX-API-DMAC7.html)
NZ (1) NZ561709A (cg-RX-API-DMAC7.html)
RU (1) RU2412201C2 (cg-RX-API-DMAC7.html)
WO (1) WO2006113402A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200708738B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7455834B2 (en) * 2002-06-29 2008-11-25 Genentech, Inc. Methods and compositions for modulating and detecting WISP activity
BR112014019741A2 (pt) 2012-02-11 2020-12-22 Genentech, Inc Usos de um antagonista da via wnt, uso de uma terapia anticâncer, método de identificação de um indivíduo com câncer, métodos para prever, método de inibição da proliferação de uma célula de câncer, uso de um antagonista da translocação de r-spondina e antagonista da translocação de r-spondina isolado
KR20150134346A (ko) * 2013-03-27 2015-12-01 지이 헬스케어 에이에스 진단 조성물을 제조하기 위한 방법 및 시약
CN106456732A (zh) * 2014-04-15 2017-02-22 索伦托治疗有限公司 结合wisp1的抗体疗法
KR102011366B1 (ko) * 2016-11-17 2019-10-14 연세대학교 산학협력단 암 전이 억제제의 스크리닝 방법
EP4365299A3 (en) * 2018-05-17 2024-08-07 Olives Biotherapeutics Inc. Pharmaceutical composition comprising ccn5 as active ingredient for preventing or treating retinal disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999021998A1 (en) * 1997-10-29 1999-05-06 Genentech, Inc. Wnt-1 induced secreted polypeptides: wisp-1, -2 and -3
WO2004003158A2 (en) * 2002-06-29 2004-01-08 Genentech, Inc. Methods and compositions for modulating and detecting wisp activity

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
PT1623990E (pt) 1999-03-08 2008-03-18 Genentech Inc Composições e métodos para o tratamento de tumores
US7455834B2 (en) 2002-06-29 2008-11-25 Genentech, Inc. Methods and compositions for modulating and detecting WISP activity
JP2007505131A (ja) 2003-09-11 2007-03-08 ジェネンテック・インコーポレーテッド Wispアンタゴニストの使用方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999021998A1 (en) * 1997-10-29 1999-05-06 Genentech, Inc. Wnt-1 induced secreted polypeptides: wisp-1, -2 and -3
WO2004003158A2 (en) * 2002-06-29 2004-01-08 Genentech, Inc. Methods and compositions for modulating and detecting wisp activity

Also Published As

Publication number Publication date
CN101198623A (zh) 2008-06-11
ES2388993T3 (es) 2012-10-22
IL186095A (en) 2012-10-31
CA2604933C (en) 2014-07-08
CN101198623B (zh) 2013-06-12
AU2006236649A2 (en) 2008-07-24
IL186095A0 (en) 2008-01-20
ZA200708738B (en) 2009-01-28
BRPI0612184A8 (pt) 2017-12-26
US7732567B2 (en) 2010-06-08
NZ561709A (en) 2009-12-24
AU2006236649A1 (en) 2006-10-26
CA2604933A1 (en) 2006-10-26
JP2008537958A (ja) 2008-10-02
MX2007012798A (es) 2007-11-20
KR101320261B1 (ko) 2013-10-22
HK1112470A1 (en) 2008-09-05
EP1869086A1 (en) 2007-12-26
US20060147453A1 (en) 2006-07-06
RU2007142005A (ru) 2009-05-20
KR20080003344A (ko) 2008-01-07
RU2412201C2 (ru) 2011-02-20
JP4979684B2 (ja) 2012-07-18
EP1869086B1 (en) 2012-07-18
WO2006113402A1 (en) 2006-10-26
BRPI0612184A2 (pt) 2011-12-20
NO20075825L (no) 2008-01-11
US20090148448A1 (en) 2009-06-11
US7455834B2 (en) 2008-11-25

Similar Documents

Publication Publication Date Title
US20060015952A1 (en) Screening assays and methods of tumor treatment
JP5489465B2 (ja) Dll4アンタゴニストによって腫瘍増殖を阻害する治療方法
CA2445611A1 (en) P-cadherin as a target for anti-cancer therapy
US7732567B2 (en) Methods and compositions for modulating and detecting wisp activity
RU2365382C2 (ru) Композиции и способы для регуляции развития сосудов
CA2489515C (en) Methods and compositions for modulating and detecting wisp activity
AU2004272066B2 (en) Methods of using WISP antagonists
ES2349162T3 (es) Procedimientos y composiciones para modular y detectar la actividad de wisp.
HK1112470B (en) Methods and compositions for modulating and detecting wisp activity

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 26 JUN 2008

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired